VTRS - Regeneron Celebrates Legal Win: Court Upholds Eylea Medication Patent | Benzinga
Wednesday, a court ruling that found Viatris Inc's (NASDAQ: VTRS) replica of Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) eye drug, Eylea (aflibercept), violated patent rights.
The decision from the U.S. District Court for the Northern District of West Virginia notes that Viatris (formerly Mylan) has not shown clear and convincing evidence supporting the anticipation or obviousness, under prior art, of claims 4, 7, 9, 11, 14, 15, 16, and 17 of the ’865 Patent, nor their invalidity under 35 U.S.C. § 112 due to lack of written description, enablement, or indefiniteness.
Regarding claim 6 of the ...